Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treosulfan-based conditioning for bone marrow failure diseases
NCT04965597Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Apr 2022
- Primary completion
- Feb 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of treosulfan in bone marrow failure syndrome (BMFS), Amegakaryocytic Thrombocytopenia (CAMT), Diamond-Blackfan anemia (DBA) and 6 more, sponsored by Fred Hutchinson Cancer Center. Started Apr 2022; status: completed.
02
Drugs
treosulfan
03
Conditions
bone marrow failure syndrome (BMFS)Amegakaryocytic Thrombocytopenia (CAMT)Diamond-Blackfan anemia (DBA)hereditary sideroblastic anemiaparoxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT04965597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965597.